About Index Trending news
Analyze
Pricing
Forbion Capital Partners

Forbion Capital Partners

Forbion Capital Partners

Forbion Capital Partners invests in Life Sciences and Biomedical Technology companies developing worldclass drugs and technologies, with a clear focus on product development. .

Elsewhere

Contributors to this profile

Alexa global traffic share

24 Jul 2017
$30,000,000
Venture capital (Series C)
CD-Venture, Arcus Ventures, NGN Capital, +4

citybizlist : Exosome Diagnostics Raises $30M Series C

citybizlist
07 Feb 2017

Prexton Therapeutics, participated by Ysios Capital, Series B financing round raises € 29 millions to advance its novel Parkinson’s therapeutic.es

capital-riesgo
+1
05 Jan 2017
£23,000,000
Venture capital (Series B)

NeRRE Therapeutics picks up Series B funds

PE Hub
+2
06 Sep 2016
€15,000,000
Venture capital (Series A)
Sunstone Capital, MP Healthcare Venture Management, NRW.BANK, +3

Rigontec Raises €15M in Third Closing of Series A Funding

FinSMEs
15 Jun 2016
€22,000,000
Venture capital (Series B)
EMBL Ventures, Forbion Capital Partners, Edmond de Rothschild Investment Partners, +2

Allecra Therapeutics Announces €22 Million Series B Financing

prnewswire
+1
07 Jan 2016
$60,000,000
Venture capital (Series B)
Tiger Management, Qiagen, Arcus Ventures, +4

Exosome Diagnostics Completes $60 Million Series B Financing

businesswire
+2
02 Sep 2015
$17,600,000
Venture capital (Series B)
Tiger Management, CD-Venture, Arcus Ventures, +2

Exosome Diagnostics Raises $17.6 Million in Second Round Series B Financing

BioPortfolio
11 Mar 2014
$27,000,000
Venture capital (Series B)
b-to-v Partners AG, Qiagen, Arcus Ventures, +2

Exosome Diagnostics raises USD 27m in Series B Financing Partners AG

b-to-v
+1
25 Jul 2012
04 Feb 2011
$48,268,413
Venture capital (Series B)
Advent Venture Partners, Auriga Partners, Crédit Agricole Private Equity, +5
11 May 2010
$20,000,000
Venture capital (Series A)
12 Mar 2010
30 Mar 2009
$40,000,000
Venture capital (Series F)
Crédit Agricole Private Equity, Scottish Equity Partners (SEP), New Science Ventures, +4